Currently, there are 79.67M common shares owned by the public and among those 71.21M shares have been available to trade.
The company’s stock has a 5-day price change of 18.90% and -6.12% over the past three months. AKRO shares are trading 70.99% year to date (YTD), with the 12-month market performance up to 129.47% higher. It has a 12-month low price of $17.86 and touched a high of $58.40 over the same period. AKRO has an average intraday trading volume of 1.14 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 13.46%, 15.31%, and 36.68% respectively.
Institutional ownership of Akero Therapeutics Inc (NASDAQ: AKRO) shares accounts for 101.94% of the company’s 79.67M shares outstanding.
It has a market capitalization of $3.79B and a beta (3y monthly) value of -0.27. The earnings-per-share (ttm) stands at -$3.75. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.86% over the week and 6.75% over the month.
Analysts forecast that Akero Therapeutics Inc (AKRO) will achieve an EPS of -0.82 for the current quarter, -0.95 for the next quarter and -4.47 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.94 while analysts give the company a high EPS estimate of -0.94. Comparatively, EPS for the current quarter was -0.81 a year ago. Earnings per share for the fiscal year are expected to decrease by -3.81%, and -13.30% over the next financial year. EPS should shrink at an annualized rate of -8.83% over the next five years, compared to -5.28% over the past 5-year period.
Looking at the support for the AKRO, a number of firms have released research notes about the stock. BofA Securities stated their Buy rating for the stock in a research note on January 30, 2025, with the firm’s price target at $35-$63. H.C. Wainwright coverage for the Akero Therapeutics Inc (AKRO) stock in a research note released on January 27, 2025 offered a Buy rating with a price target of $72. Citigroup was of a view on November 18, 2024 that the stock is Buy, while BofA Securities gave the stock Neutral rating on April 22, 2024, issuing a price target of $30. Cantor Fitzgerald on their part issued Overweight rating on September 19, 2023.
